News

Therapy resistance decoded
Enlarge image

ScienceFrance

Therapy resistance decoded

03.12.2012 - French researchers have identified how the body’s immune systems triggers therapy resistance to the cancer drugs gemcitabine and 5-fluorouracil.

The researchers, headed by François Ghiringhelli from INSERM in Dijon, found that in mice, the drugs activate a protein complex, termed Nlrp3 inflammasome, in myeloid derived suppressor cells. This activation leads to the release of the immune cell interleukin (IL)-1 beta, which then skews T immune cells to produce protumorigenic IL-17 and results in enhanced growth of tumours in mice (Nature Medicine, doi: 10.1038/nm.2999). 

The chemotherapeutics were more efficacious at inhibiting tumour growth in mice lacking Nlrp3 or IL-17, or treated with an IL-1 receptor antagonist. The findings suggest that targeting the inflammasome pathway in conjunction with chemotherapy may improve its tumour killing efficacy by preventing the induction of protumorigenic immune responses.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/therapy-resistance-decoded.html

EU

04.09.2015 Crowdfinancing has just recently emerged as a financing instrument in the Life Sciences. A new report lists 42 European companies in the sector that have raised a total of almost €23m.

DiabetesFrance

01.09.2015 Sanofi is partnering up with Google’s life sciences team with an ambitious goal: to change the face of diabetes management.

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EVOLVA (CH)1.49 CHF12.03%
  • TIGENIX (B)1.23 EUR9.82%
  • OREXO (S)49.10 SEK8.39%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-11.67%
  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • PROTHENA PLC (IE)52.70 USD-6.54%

TOP

  • KARO BIO (S)41.90 SEK2568.8%
  • BIOTECH PHARMACON (N)16.80 NOK80.6%
  • TRANSGENE (F)4.86 EUR75.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-49.6%
  • THROMBOGENICS (B)2.85 EUR-42.1%

TOP

  • KARO BIO (S)41.90 SEK4661.4%
  • ADOCIA (F)89.30 EUR409.1%
  • GALAPAGOS (B)53.25 EUR325.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-81.7%
  • BIOTEST (D)20.30 EUR-76.5%

No liability assumed, Date: 03.09.2015